CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net loss	$ (236,455)	$ (215,524)	$ (285,405)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,441	4,481	3,801
Amortization and accretion income, net	(3,451)	(1,315)	226
Share-based compensation	60,450	51,313	49,145
Net gain from the sale of VIBATIV business		(6,056)
Other-than-temporary impairment loss			8,000
Inventory write-down			740
Amortization of right-of-use assets	3,224
Amounts due from TRC, LLC	(23,152)	(5,152)
Other	146	(43)	10
Changes in operating assets and liabilities:
Accounts receivable	620	1,633	(1,607)
Receivables from collaborative arrangements	(11,943)	(2,944)	1,967
Prepaid taxes			2,788
Other prepaid and current assets	(634)	(2,400)	(1,489)
Inventories		(1,629)	(7,301)
Tax receivable	(3,700)	8,191	(7,890)
Other assets	(358)	45	(354)
Accounts payable	(4,274)	3,575	3,796
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	10,626	(12,357)	8,332
Accrued interest payable	2,573	1,841	21
Deferred rent		4,308	(298)
Deferred revenue	(31,245)	69,224	17
Operating lease liabilities	(2,317)
Other long-term liabilities	(4,748)	(10,058)	24,449
Net cash used in operating activities	(238,197)	(112,867)	(201,052)
Investing activities
Purchases of property and equipment	(3,176)	(7,240)	(2,406)
Purchases of marketable securities	(423,898)	(183,261)	(288,791)
Maturities of marketable securities	339,018	347,192	234,864
Proceeds from the sale of VIBATIV business, net	5,000	20,000
Proceeds from the sale of fixed assets	5	17
Net cash (used in) provided by investing activities	(83,051)	176,708	(56,333)
Financing activities
Proceeds from issuance of notes, net		229,441
Principal payment on notes	(2,152)
Proceeds from ESPP purchases	3,474	4,173	3,980
Proceeds from option exercises	3,142	1,393	6,236
Repurchase of shares to satisfy tax withholding	(3,173)	(9,807)	(8,560)
Net cash provided by financing activities	1,291	225,200	1,656
Net (decrease) increase in cash, cash equivalents, and restricted cash	(319,957)	289,041	(255,729)
Cash, cash equivalents, and restricted cash at beginning of period	378,854	89,813	345,542
Cash, cash equivalents, and restricted cash at end of period	58,897	378,854	89,813
Supplemental disclosure of cash flow information
Cash paid for interest	26,178	7,475	7,454
Cash paid (received) for income taxes, net	22	$ (7,316)	$ 4,929
Right-of-use assets obtained in exchange for lease obligations (1)	$ 49,847